Company intelligence / Profile preview
Wanbang Biopharmaceuticals
Xuzhou, Jiangsu, Chinachinawanbang.com ↗
- Ownership
- Private
- Employees
- ~5000
- Development stage
- Commercial
01
Overview
The company has a strong commercial portfolio with leading positions in diabetes care and related chronic diseases. It has several approved recombinant insulins and analogues, EPO products, heparin sodium, febuxostat tablets for hyperuricemia/gout, glimepiride tablets for diabetes, calcium dobesilate capsules for vascular complications. Some innovative programs are in late-stage clinical trials or registration phases.
- Therapeutic areas
- Metabolic DisordersOncologyEndocrinologyRheumatologyCardiovascularNephrology
- Modalities
- Small moleculeRecombinant proteinBiosimilarHormoneHerbal medicineBiologic
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
D-Pharm Israel
Beyond the preview
Go deeper on Wanbang Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wanbang Biopharmaceuticals.